Pylarify radiopharm
Ended Awarded Last action
- Contract number
- 36C25224F0232
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,000,789
Award facts
- Contract value 100% obligated
- $1,000,789.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$20,478 | |
| Funding Only Action | $46,913 | |
| Funding Only Action | $180,436 | |
| Original award | $793,918 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 12 (VISN 12) awarded a delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging Inc., for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical products. This contract, valued at $1,000,789.28 on a firm fixed-price basis with no set-aside designation, is scheduled for completion by August 31, 2025. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer, providing critical diagnostic capabilities across the VA healthcare system. Performance will occur at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts.
This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master contract vehicle that enables streamlined procurement of specialized radiopharmaceutical supplies across federal healthcare providers. Progenics Pharmaceuticals has established itself as a primary supplier to the VA system, holding multiple blanket purchase agreements with individual VISNs valued up to $9.07 million and a $290 million Federal Supply Schedule contract awarded in April 2025 extending through March 2030. The company's extensive federal contracting history includes over 150 individual contract awards from the VA, Defense Health Agency, and National Institutes of Health, positioning it as a leading supplier of diagnostic imaging agents for oncology applications within federal healthcare.
Quick answers
Who was awarded contract 36C25224F0232?
36C25224F0232 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on September 1, 2024.
How much is contract 36C25224F0232 worth?
The government has obligated $1,000,789 on 36C25224F0232.
Is contract 36C25224F0232 an order under another contract?
Yes. 36C25224F0232 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25224F0232 competed?
The extent of competition for 36C25224F0232 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award